Gain-of-function of TRPM4 predisposes mice to psoriasiform dermatitis

Daisuke Yamada¹, Simon Vu², Xuesong Wu³, Zhenrui Shi³, Desiree Morris⁴, Joshua D. Bloomstein¹, Mindy Huynh¹, Jie Zheng² and Samuel T. Hwang*¹

¹Department of Dermatology, University of California, Davis, Sacramento, CA, United States, ²Department of Physiology and Membrane Biology, University of California, Davis, Davis, CA, United States, ³Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, ⁴Kirk Kerkorian School of Medicine at University of Nevada, Las Vegas, Las, Vegas, NV, United States

Transient receptor potential melastatin 4 (TRPM4) is a Ca²⁺-activated, monovalent cation channel that is expressed in a wide range of cells. We previously reported two gain-of-function (GoF) mutations of TRPM4 as the cause of progressive symmetric erythrokeratodermia (PSEK), which shares similar clinical and histopathological features with psoriasis. Using CRISPR/Cas9 technology, we generated TRPM4I1029M mice that have the equivalent mutation to one of the two genetic mutations found in human PSEK (equivalent to human TRPM4I1033M). Using this mutant mice, we examined the effects of TRPM4 GoF at the cellular and phenotypic levels to elucidate the pathological mechanisms underlying PSEK. In the absence of experimental stimulation, TRPM4I1029M mice did not show a phenotype. When treated with imiquimod (IMQ), however, TRPM4I1029M mice were predisposed to more severe psoriasiform dermatitis (PsD) than wild-type (WT), which was characterized by greater accumulation of CCR6-expressing γδ T cells and higher mRNA levels of Il17a. In TRPM4I1029M mice, dendritic cells showed enhanced migration and keratinocytes exhibited increased proliferation. Moreover, a TRPM4 inhibitor, glibenclamide, ameliorated PsD in WT and TRPM4I1029M mice. Our results indicate elevated TRPM4 activities boosted susceptibility to cutaneous stimuli, likely through elevation of membrane potential and alteration of downstream cellular signaling, resulting in enhanced inflammation. Our results further suggest a possible therapeutic application of TRPM4 inhibitors in psoriasis.

KEYWORDS
TRPM4, keratinocyte, dendritic cell, psoriasis, imiquimod (IMQ), mouse model, progressive symmetric erythrokeratodermia, glibenclamide
Introduction

Transient receptor potential melastatin 4 (TRPM4) is a Ca^{2+}-activated nonselective cation (CAN) channel involved in diverse physiological processes and implicated in several human hereditary diseases (1, 2). Increase in TRPM4 activity induced by elevating intracellular Ca^{2+} concentration is expected to depolarize the membrane potential and induce subsequent cellular response (3). Like most transient receptor potential (TRP) channels, TRPM4 is thought to be tetramer made of four subunits, each of which containing six transmembrane segments and intracellularly located N- and C-terminal. Recently, its cryo-EM structure was reported by four independent groups, showing a four-fold symmetrical complex (4–7). TRPM4 proteins are found in various cell types and determine important functions, including insulin secretion in pancreatic beta cells, cardiac excitation in ventricular cells, immune response in lymphocytes, dendritic cells (DCs), and mast cells as well as excitability and contractility in vascular smooth muscle cells (8–14). Several heterozygous mutations of TRPM4, leading to gain-of-function (GoF) have been identified in familial heart conduction diseases (15, 16), signifying its importance in maintaining cellular homeostasis. Recently, two GoF mutations (p.I1033M and p.I1040T) in TRPM4 were found in patients with an autosomal dominant-inherited skin disease termed progressive symmetric erythrokeratodermia (PSEK). Both of the mutation sites are located in ion permeation pore region. The mutant channels were found to induce increased Ca^{2+} in human PSEK (equivalent to human TRPM4 I1033M). The equivalent mutation to one of the two genetic mutations found in patients with PSEK produces a four-fold symmetrical complex without altering EAE-relevant immune function (21). While these studies highlighted the role of TRPM4 in maintaining cellular homeostasis including the immune system, it remains unclear how TRPM4 GoF mutants lead to PSEK and other human diseases. To address this question, we generated TRPM4 GoF mice using the CRISPR/Cas9 method which have the equivalent mutation to one of the two genetic mutations found in human PSEK (equivalent to human TRPM4 I1033M). The mutation site is located in ion permeation pore region (Supplementary Figure 1). The TRPM4 GoF mice did not show any skin phenotype in the absence of stimulation, however, the results of our in vitro experiments indicated that this mutation affects the membrane potential and proliferation of keratinocytes, suggesting that cells harboring GoF mutant TRPM4 channels might be more susceptible to disease-causing environmental stimuli. Considering that the skin manifestations and histopathological findings of PSEK are similar to those of psoriasis (17) as manifested by thickened, red scaly plaques, we employed an imiquimod (IMQ)-induced PsD model. When stimulated by IMQ, TRPM4 GoF mice showed enhanced cutaneous inflammation. Both GoF mice and wild-type (WT) littersmates showed reduction of IMQ-induced dermatitis when treated with glibenclamide, a TRPM4 inhibitor. Thus, TRPM4 plays a critical role in regulating psoriasis-like features in mice, which possibly explains the resemblance of the skin lesions in PSEK patients to human psoriasis and may point to TRPM4 as a relevant target in psoriasis.

Materials and methods

Generation of TRPM4 mutant (I1029M) mice (C57BL/6J background)

To generate TRPM4 I1029M mice, we obtained purified Cas9, a TRPM4-targeting guide RNA (gRNA; 5’-CAGGGTTAGGCAACAGGATATTGG-3’) that targets Cas9 to a site near the I1029 codon, and donor oligos for HDR resulting in p.I1029M (c.C3087G) mutations (HDR donor sequence; 5’-
genotyping of the mice, we used RT-qPCR of mutant pathogen free conditions throughout this study. For the heterozygous mice whereas no mutant i.e., homozygous mouse expressed twice as high mutant mouse. All animal experiments were performed under protocols approved by the Institutional Animal Care and Use Committee at the University of California, Davis.

Primary keratinocyte isolation and culture

Adult mouse keratinocytes were cultured following the procedure described by Li (22). Briefly, the tail skin from an adult mouse was digested in dispase digestion buffer, which contains 4 mg/ml dispase II in supplemented KC growth medium (KC basal medium with 0.06 mM CaCl2, Defined Growth Supplement, antibiotics) overnight 4°C. Epidermal sheet was removed, digested in trypsin-based digestion solution. Then cells were filtered and seeded in supplemented KC growth medium in culture dishes pre-coated with a collagen-based coating material. For WST-1 assay, cells were seeded at 1.0x10^5 cells/well in a 96-well plate. After 24 hours of incubation, medium was changed and thereafter WST-1 (Sigma-Aldrich, St. Louis, MO) was added to each well. For cell counting, 1.0x10^5 cells/well were seeded in supplemented KC growth medium in culture dishes pre-coated with a collagen-based coating material. For WST-1 assay, cells were seeded at 1.0x10^5 cells/well in a 96-well plate. After 24 hours of incubation, medium was changed and thereafter WST-1 (Sigma-Aldrich, St. Louis, MO) was added to each well. For cell counting, 1.0x10^5 cells/well were seeded in a 24-well plate. After 4 days of incubation, cell numbers were counted using a hemocytometer.

Electrophysiology

Recordings were performed using a HEKA EPC10 amplifier with PatchMaster software. The bath solution consisted of 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 10 mM Glucose, pH 7.4; the pipette solution consisted of 150 mM K-Asp, 5 mM KCl, 10 mM HEPES, 10 µM PIP2, 2 mM EGTA, 1.8 mM CaCl2, pH 7.4 (resulting in 10 µM free Ca2+, calculated by MAXCHELATOR program, http://maxchelator.stanford.edu). Patch pipettes were fashioned from borosilicate glass and fire polished within the range of 3-5 MΩ. All recordings were performed at room temperature (~22°C). Membrane potential was recorded in the whole-cell patch configuration. The liquid junction potentials were tested experimentally and adjusted accordingly.

Cell cycle assay

Cell cycle assay was performed following the procedure described by Kim (23). Briefly, primary keratinocytes isolated from adult mouse tail were fixed in ice cold 70% ethanol. Then, the cells were stained with anti-Ki-67 antibody (Cat# 1512111, BioLegend) and propidium iodide containing RNase (Cat# 4087, Cell Signaling Technologies).

IMQ-induced PsD model

IMQ-induced PsD model was described previously (24). 50 mg of 5% IMQ (Aldara, 3M Pharmaceuticals) in total was applied once daily to both sides of both ears for 5 consecutive days. Vanicream (Pharmaceutical Specialties, Cleveland, GA, USA) was applied on ears of WT mice as a vehicle control.

Scoring severity of skin inflammation

To score the severity of inflammation of the ear skin, an objective scoring system was used as described before (24). Briefly, erythema, scaling, and thickening were scored independently on a scale from 0 to 4: 0, none; 1, slight; 2, moderate; 3, marked; 4, very marked. We calculated the cumulative score (erythema plus scaling plus thickening) as psoriasis severity index (PSI) score (scale 0–12). Ear skin thickness was measured with a thickness gauge (Peacock, Ozaki, MFG.CO., LTD, Japan) having 0.01 mm accuracy.

Histopathological analysis and immunohistochemistry

Formaldehyde-fixed, paraffin-embedded ear skin samples were stained with H&E using standard procedures. Images were acquired using a Nikon Optiphot 2 microscope (Nikon, Tokyo, Japan). Epidermal thickness was measured with a computer-assisted image analysis software. For immunohistochemical analysis, skin sections were incubated with primary antibodies against murine p-STAT3, followed by the appropriate secondary antibodies. Rinsed sections were counterstained with hematoxylin.

DNFB-induced contact hypersensitivity

One day after shaving the back hair with electrical clippers, the back skin was treated with 50 µl of 0.5% DNFB (1-fluoro-2,4-dinitrobenzene) (Sigma-Aldrich, St. Louis, MO) in a 4:1 mixture...
of acetone and olive oil. Five days later, the mice were challenged with 40 µl 0.2% DNFB. WT mice without sensitization served as a control group. Ear thickness was evaluated before challenge and after challenge (24 hours, 48 hours, and 72 hours).

**Croton oil-induced irritant contact dermatitis**

25 µl of 2% croton oil (in a 4:1 mixture of acetone and olive oil) was applied to the dorsal side of the ear. Ear thickness was evaluated 2, 4, 6, and 24 hours after challenge. WT mice applied with 4:1 mixture of acetone and olive oil served as a vehicle control group.

**Flow cytometry**

Anti–mouse γδ-TCR (clone GL3), CD3 (17A2), CD45 (30-F11), CCR6 (29-2L17), CD11b (M1/70), CD11c (N418), and Ly6G (IA8) antibodies were from BioLegend (San Diego, CA). Anti-mouse IL-17A (eBio17B7) antibody was from eBioscience (San Diego, CA). Flow cytometry was performed and analyzed using an Accuri C6 (BD Biosciences, San Jose, CA). After recovery of mouse ears, the ears were cut into small pieces with a blade. To obtain cell suspensions, small pieces of ear skin were digested with Liberase TM (Roche, Mannheim, Germany) and DNase I (Sigma-Aldrich, St. Louis, MO) with addition of 5% fetal bovine serum for 90 minutes before passing tissue through a 100-µm cell strainer. Anti-mouse CD16/32 (BD, San Jose, CA) were added to cells prior to staining to block binding to Fc receptors. Flow gating for CCR6+ γδ-low T cells was performed using a gating strategy described in detail in our previous reports (25, 26). Representative flow gating for the population is shown in Supplementary Figure 2. Intracellular staining for IL-17A was done after incubating cells for 5 hours with cell stimulation cocktail plus protein transport inhibitors (eBioscience 00-4975-93).

**Quantitative real-time PCR**

Total RNA of mouse ear skin was extracted using a RNeasy Fibrous Tissue Kit (Qiagen, Hilden, Germany). Quantitative real-time PCR was performed using CFX connect Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Predesigned primers were obtained from Integrated DNA Technologies, Inc (Skokie, IL).

**DC migration assay**

We applied 100µl of 1% FITC (Sigma-Aldrich, St. Louis, MO) solution in acetone and dibutyl phthalate (1:1) on mouse ears to label phagocytic antigen presentation cells, such as dermal and epidermal DCs, and quantified their migration from skin to regional LN. Six hours after the FITC application, we collected the cervical LNs and quantified the FITC+ DCs by flow cytometry.

**Glibenclamide treatment**

We administered 10 µg glibenclamide daily by intraperitoneal injections to all mice in the treatment group (21). We daily dissolved 25 µg glibenclamide (Sigma-Aldrich, St. Louis, MO) in 5 ml DMSO and diluted 200 µl of this solution in 9.8 ml PBS. Mice received 100 µl of this solution or 2% DMSO in PBS as vehicle control.

**Statistical analysis**

All data are shown as mean ± SEM. Data were analyzed using GraphPad Prism version 8 (GraphPad Software, San Diego, CA). A two-sided unpaired Student’s t-test was used to compare two groups, and one-way analysis of variance (27) with Tukey’s post hoc test was used for multiple comparisons unless otherwise indicated. A p-value less than 0.05 was considered statistically significant.

**Results**

**TRPM4 I1029M mutant mice show minimum phenotype without stimulation**

To examine if mice harboring the human PSEK mutation can spontaneously exhibit a similar skin phenotype, we generated TRPM4 I1029M mutant mice using CRISPR/Cas9 methodology (Figure 1A; see Materials and Methods). This mutation is equivalent to human I1033M mutation. Briefly, purified Cas9, TRPM4-targeting guide RNA (gRNA), and homology directed repair (HDR) oligos were injected into C57BL/6J zygotes. The resulting pups were genotyped by amplifying a 374 bp region flanking the I1029M site and subsequent Sanger sequencing. Since clinical manifestations of PSEK are erythematous hyperkeratotic plaques at hands, feet, or periorificial sites, we observed those sites carefully. TRPM4 I1029M GoF mice, housed under standard specific-pathogen free conditions, did not show an obvious skin phenotype throughout the first 5 months of their lives (Figure 1B). Because other TRPM4 mutations in humans have been associated with familial heart block (9), we performed electrocardiograms in our mutant mice and found no abnormalities compared to WT siblings (data not shown). This is consistent with clinical observations from PSEK patients who do not have cardiac abnormalities (17).
TRPM4 I1029M mutant keratinocytes exhibit an elevated resting membrane potential

Since we did not find obvious skin changes in TRPM4 GoF mice in vivo, we next asked if cells harboring this mutation show any changes compared to WT cells in vitro. Previously, we reported that the two TRPM4 missense mutations (I1033M, I1040T; human) exhibited an elevated resting membrane potential in HEK293 cells (17). To determine if this phenomenon occurs in TRPM4 mutant cells in vitro, we compared the resting membrane potential in isolated primary keratinocytes from TRPM4 I1029M homozygous, heterozygous, and WT mice. Indeed, the resting membrane potential was elevated in homozygous and heterozygous keratinocytes compared to WT (-23.6 ± 4.3 mV, -22.2 ± 3.7 mV; -54.6 ± 5.8 mV; homozygous, heterozygous, and WT, respectively) (Figure 1C). These results confirmed that TRPM4 activity is indeed enhanced (as expected) with the I1029M mutation. Notably, there was no obvious difference between homozygous and heterozygous mutation with regard to the resting membrane potential. Thus, despite similarities in baseline skin characteristics in TRPM4 mutant and WT mice in vivo, keratinocytes from the GoF mutant show elevated resting membrane potential.

TRPM4 I1029M mutant keratinocytes exhibit enhanced proliferation

Since one of the major histological characteristics of PSEK is epidermal hyperplasia, we next asked whether TRPM4 I1029M mutation alters keratinocyte proliferation. In the electrophysiological study, we observed no substantial difference in resting membrane potential between homozygous and heterozygous keratinocytes compared to WT (-23.6 ± 4.3 mV, -22.2 ± 3.7 mV, -54.6 ± 5.8 mV; homozygous, heterozygous, and WT, respectively) (Figure 1C). This suggested that a single heterozygous mutation was enough to alter cellular physiology and was consistent with the autosomal dominant
genetic inheritance of PSEK. While homozygous mutant mice were generated along with heterozygous TRPM4 GoF mutant mice, our in vivo experiments focused on heterozygous mice (Het I1029M) in order to replicate the human PSEK disease, which is only known to occur in the heterozygous state. Comparing Het I1029M and WT keratinocytes, we found that I1029M keratinocytes were more likely to be in G1, S, G2/M phase or S phase (Figure 1D). WST-1 assay was performed to examine the number of viable cells after 24 hours of incubation with equal numbers of either Het mice-derived or WT mice-derived keratinocytes. The relative cell number of Het mice-derived keratinocytes was significantly higher than those of WT mice-derived keratinocytes (Figure 1E). We performed cell counting, which also confirmed Het keratinocytes were more proliferative (Figure 1F).

Thus, these results show that the Het I1029M mutation stimulated keratinocytes proliferation in vitro.

**Het I1029M mice exhibit enhanced susceptibility to IMQ-induced psoriasiform dermatitis**

Although Het I1029M mice did not display any skin phenotype in the absence of stimulation (Figure 1B), the results of our in vitro experiments indicate that this mutation affects the membrane potentials and proliferation of keratinocytes (Figures 1C–F), suggesting that cells harboring GoF mutant TRPM4 channels might be more susceptible to disease-causing environmental stimuli. The skin manifestations and histopathological findings of PSEK are similar to those of psoriasis (17). Thus, to determine if there is a difference between Het I1029M and WT mice in response to stimulation, we used an IMQ-induced PsD model. As a vehicle control group, we applied Vanicream to WT mice. To see if the application of Vanicream alone can cause any difference between WT and Het I1029M mice, we compared WT and Het I1029M with applying Vanicream only and there was no difference between WT and Het I1029M (Supplementary Figure 3). Firstly, to determine if TRPM4 is expressed in psoriasis skin, we analyzed a publicly available RNA sequencing dataset and found that TRPM4 was expressed in both psoriasis skin lesions and healthy skin controls (Gene Expression Omnibus GSE117405). Het I1029M mice showed more severe inflammation that was characterized by increased ear thickening, erythema, and scale (Figures 2A, B). Changes in ear thickness and clinical score (as assessed by psoriasis severity index score, PSI score) were larger in Het I1029M mice versus their WT littermates (Figure 2B). Consistent with the observation that Het I1029M keratinocytes were more proliferative (Figure 1D–F), epidermal thickness was greater in Het I1029M mice than WT controls (Figure 2C). Interestingly, other parameters such as erythema and scale that reflect inflammation rather than keratinocyte proliferation also showed significant differences (Figure 2B), suggesting that this mutation could affect other aspects of inflammation in this mouse model.

Het I1029M mice do not show altered phenotype in croton oil-induced irritant contact dermatitis or DNFB-induced allergic contact dermatitis

We next asked if TRPM4 GoF mice have susceptibility to other stimuli using two other dermatitis models, i.e., croton oil-induced irritant contact dermatitis and di-nitro-fluoro-benzene (DNFB)-induced allergic contact dermatitis. However, Het I1029M mice did not show altered phenotype in these contact dermatitis models (Supplementary Figures 4, 5). In the croton oil-induced model, WT mice were treated with a 4:1 mixture of acetone and olive oil and served as a vehicle control group. In the DNFB-induced model, WT mice which received DNFB challenge only served as a control group. The results indicate that the effect of TRPM4 GoF had relatively specific functional effects in the PsD-related IMQ model compared to the other two models.

Enhanced inflammation observed in Het I1029M mice is characterized by accumulation of CCR6–expressing γδ–low T cells and higher expression levels of Il17a

We next sought to characterize the immunological features of the enhanced skin inflammation observed in Het I1029M mice. One day following the last application of IMQ (day 5), mice were sacrificed and cell suspensions from the ears were prepared. We have previously shown that CC chemokine receptor-6 positive (CCR6+) γδ–low T cells are one of the dominant sources of IL-17A and play an important role in IMQ-induced PsD (28–30). We first evaluated this cell subset by flow cytometry. Het I1029M mice showed an increased proportion of CCR6+ γδ–low T cells as well as neutrophils among CD45+ cells (Figure 2D). We next evaluated mRNA expression levels from mouse ears. mRNA expression levels of Il17a were greater in Het I1029M mice than WT (Figure 2E). This was consistent with the IHC staining of pSTAT3 where Het I1029M mice showed higher expression of pSTAT3 (Figure 2A), which is a downstream signaling of IL-17A and plays important roles in psoriatic keratinocytes (31). mRNA expression levels of other cytokines such as Il6 did not show a difference (data not shown). We next asked if IL-17A+ T cells in the regional lymph node (LN) were increased in Het I1029M mice. LN cells from non-stimulated WT or Het I1029M mice had similar rate of IL-17A+ gd–low T cells and higher expression levels of Il17a (Supplementary Figure 6). Collectively, at the immunological level, Het I1029M mice displayed augmented skin inflammation mainly characterized by enhanced Th17
response compared to WT counterparts following application of IMQ.

Enhanced accumulation of DC in Het I1029M mice

We next sought to identify a functional explanation for the enhanced dermatitis in Het I1029M mice. Since TRPM4 contributes to efficient migration of DC (13), we hypothesized that DC migration is accelerated in Het I1029M mice. To test this idea, we applied 1% FITC solution on mouse ears to label phagocytic antigen presentation cells, such as dermal and epidermal DC, to measure the efficiency of their migration from skin to regional LN. Six hours after the FITC application, we collected the cervical LNs and determined the FITC + DC. Indeed, significantly increased numbers of FITC + DC were observed in Het I1029M mice (Figure 3A), indicating that DC migration is enhanced in Het I1029M mice compared to WT mice. Moreover, this increased DC migration in Het I1029M mice was also observed under the skin was stimulated with IMQ (Figure 3B). Because DCs are one of the key players in PsD, it is possible that this increased migration of DCs contributes to the more severe inflammation observed in the mutant mice.

Glibenclamide, a TRPM4 inhibitor, attenuates IMQ-induced PsD in Het I1029M and WT mice

Since TRPM4 GoF predisposes mice to more active PsD, we predicted that a TRPM4 inhibitor may ameliorate PsD. Glibenclamide, a classic diabetes drug, is known to also act as an inhibitor of TRPM4 (21). Het I1029M and WT mice received daily IMQ application and glibenclamide i.p. injection for 5 days. Indeed, glibenclamide ameliorated IMQ-induced PsD clinically and histologically in both groups of mice (Figures 4A–C). Clinical evaluation represented by the changes in ear thickness revealed that glibenclamide significantly ameliorated IMQ-induced PsD both in WT and Het I1029M mice (Figure 4B). In addition, glibenclamide treatment reduced the epidermal thickness in Het I1029M mice. Flow cytometry of mouse ear showed that the numbers of CCR6+ γδ-low T cells and neutrophils tended (although not reaching statistical significance) to be reduced by glibenclamide in Het I1029M mice (Figure 4D). Furthermore, mRNA levels of Tnf were reduced by glibenclamide both in WT and Het I1029M mice, and Il17a, Il17f, Cxcl1, and K16 were reduced by glibenclamide in Het I1029M mice. (Figure 5). Lastly, we sought to investigate if DC migration is inhibited by glibenclamide. Glibenclamide was intraperitoneally injected, then IMQ was
applied on mice ear. On the next day of the IMQ application, 1% FITC solution was applied on mice ear. Six hours after FITC application, the regional LN was collected and evaluated by flow cytometry. Indeed, DC migration was inhibited by glibenclamide (Figure 6). Thus, a known inhibitor of TRPM4 ameliorates PsD in TRPM4 mutant as well as WT mice, suggesting that TRPM4 may have a regulatory role in PsD and possibly introducing this protein as a therapeutic target in psoriasis.

**FIGURE 3**
Enhanced accumulation of DCs is observed in Het I1029M mice. (A) 100μl of 1% FITC solution was applied on mouse ears. Six hours after the FITC application, cervical LNs were collected. Left: increased FITC+ rate among CD11c+ cells, right: increased numbers of FITC+ DCs were observed in Het I1029M mice compared to WT (n = 8). (B) DC migration assay was conducted under IMQ applied condition. Left: increased FITC+ rate among CD11c+ cells, right: increased numbers of FITC+ DCs were observed in Het I1029M mice compared to WT (n = 4). Data are presented as mean ± SEM and are representative of two independent experiments. **p < 0.01, ***p < 0.001 by using Student’s T test.

**FIGURE 4**
Glibenclamide, a TRPM4 inhibitor, attenuates IMQ-induced PsD in Het I1029M and WT mice. Het I1029M mice or WT mice received daily imiquimod application and daily glibenclamide i.p. injection for 5 days. (A) Representative photographs, histology images, and immunohistochemical images for Ki-67. (B) Changes in ear thickness (n = 8, vehicle; n = 4). (C) Histological analysis of epidermal thickness (n = 4, vehicle; n = 2). (D) Left: numbers of CCR6+ gd-low T cells per ear, right: numbers of neutrophils per ear in the lesional skin (n = 4, vehicle; n = 2), determined by flow cytometry. The data are presented as mean ± SEM. Data are representative of two independent experiments. *p < 0.05, **p < 0.01, ***<0.001 by using one-way ANOVA with Tukey's test.
Discussion

Recently, we and our collaborators reported two TRPM4 GoF mutations that we suggest are the genetic basis of PSEK (17). Though PSEK is a genetic disease, it is clinically characterized by keratotic erythema that resembles the ones observed in inflammatory skin conditions such as psoriasis (32). Therefore, we hypothesized TRPM4 was involved in not only PSEK but could potentially play a regulatory role in other inflammatory skin diseases. To investigate the role of TRPM4 in the physiology and pathophysiology of dermatitis and PSEK, we generated TRPM4 GoF mutant mice (I1029M) that have an equivalent mutation to human PSEK.

Since PSEK is a disease that develops spontaneously during early childhood without known triggers or stimulation, we carefully observed the mutant mice from birth. Interestingly, our mutant mice did not show an obvious skin phenotype (Figure 1B) despite our observation that Het I1029M keratinocytes showed increased proliferation (Figures 1D–F). We speculate that compensatory mechanisms may inhibit the tendency of the mutant keratinocytes to undergo enhanced proliferation. Another important fact is that PSEK is a spontaneously resolving disease. We hypothesize that some unknown inflammatory trigger that is present in humans (and not present in mice) may be the necessary trigger for the development of PSEK. We further hypothesize that this stimulus may resolve spontaneously as children get older, leading to the eventual disappearance of the PSEK skin disease in older patients. While we have not identified the exact trigger in human PSEK, it is worthwhile noting that several common skin diseases, including atopic dermatitis and acne, that have complex interactions with skin microbiota, occur in younger individuals and tend to resolve in adults.

When subjected to IMQ topical application, a standard model of human psoriasis, Het I1029M mice showed exacerbated inflammation compared to WT (Figure 2A). This inflammation was characterized by higher mRNA expression levels of Il17a and accumulation of CCR6+ γδ T cells that is reported to be a major source of IL-17A in this model (Figures 2D, E). Then, we sought to investigate what cells are affected and contribute to the exacerbated inflammation in Het I1029M mice. Among the inflammatory cells, DCs are known to have a pivotal role in psoriasis. Importantly, TRPM4 is reported to be essential for DC migration (13). Our migration assay results clearly demonstrated that DC migration is enhanced in Het I1029M mice. In summary, the TRPM4 mutation may have two independent impacts on the exacerbation of PsD via increased proliferation of keratinocytes and enhanced migration of DCs. In Het I1029M mice, DC migration to the regional LN is enhanced (Figure 3A). These migrated DCs potentially stimulate LN T cells leading to expand IL-17A producing γδ T cells. As a result, increased accumulation of IL-17A producing γδ T cells in the lesions could lead to IL-17A-mediated dermatitis. Because keratinocytes are not the predominant cells that directly respond to IMQ, other cell types such as DCs expressing TLR7 should be activated by IMQ, resulting in the production of proinflammatory cytokines that then secondarily activate keratinocytes that express TRPM4. Recently in microglia, TRPM4-mediated NLRP3 inflammasome activation was reported (33). It is possible that TRPM4 GoF may mediate inflammasome-mediated signaling in the context of skin inflammation although this should be tested in future studies.

Interestingly, exaggerated inflammation in Het I1029M mice was only observed in IMQ-induced psoriasisform dermatitis model, but not observed in the croton oil-induced or DNFB-induced dermatitis models. Our results at least showed that DC migration and keratinocyte proliferation are associated with TRPM4 GoF. We
speculate that diseases in which DC migration and keratinocyte proliferation play important roles would be greatly affected by TRPM4 GoF. As both DC migration and keratinocyte proliferation are the important features in psoriasis-like skin inflammation, that may explain why this GoF mutation specifically enhanced IMQ-induced skin inflammation. Clearly, other models of skin inflammation (such as tape-stripping) could be tested in the future to examine the specificity of TRPM4-mediated signaling.

Consequently, an important question is whether or not this exacerbated PsD in Het I1029M mice or spontaneous PsD in WT mice can be ameliorated by a TRPM4 inhibitor. TRPM4 channels can exist as homomers or assemble with sulfonylurea receptors (SURs) as complexes (34, 35). Glibenclamide inhibits SUR-TRPM4 heteromeric channels (34), but it may also directly inhibit TRPM4 channels (36, 37). Glibenclamide clearly inhibited DC migration to the regional LN (Figure 6). These results help to re-affirm that the enhanced PsD observed in Het mice is a direct consequence of the TRPM4 channel. Since both WT and Het TRPM4 mice had reduced PsD when treated with glibenclamide, we suggest that TRPM4 may be a new and relevant target for psoriasis in humans.

There are several limitations in this study. One of the limitations is some of the results showed trends, but did not reach statistical significance due to the lack of availability of larger numbers of mutant mice. However, we note that these trends were observed in multiple experiments. Furthermore, we used only glibenclamide as a TRPM4 inhibitor because it is most widely used TRPM4 inhibitor used in vivo. Future studies using TRPM4 inhibitors other than glibenclamide are warranted. Lastly, while we were able to study keratinocytes and dendritic cells in greater detail, one limitation of this study is that we were not able to assess the biochemical characteristics of other immune cells such as T cells that might also be impacted by TRPM4 function. Because of multiple known functions of TRPM4 in different cell types, it is possible that TRPM4 GoF mutation regulates PsD in several ways, but, of note, a TRPM4 inhibitor blocks PsD in WT as well as TRPM4 GoF mice. Overall, these data indicate that TRPM4 may contribute to PsD in humans and that it warrants further study as a target in human psoriasis.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author/s.
Ethics statement

The animal study was reviewed and approved by Institutional Animal Care and Use Committee, University of California, Davis.

Author contributions

DY, SV, JZ, and SH designed the experiments, analyzed the data and wrote the manuscript. XW, ZS, and MH acquired, analyzed and interpreted the data. DM and JB analyzed and interpreted the data. All authors contributed to the article and approved the submitted version.

Funding

Research reported in this publication was supported by the National Institutes of Health under award number 1R01NS128180-01 (to JZ) and Department of Dermatology Seed Grant (to SH).

References

1. Kruse M, Pongs O. TRPM4 channels in the cardiovascular system. Curr Opin Pharmacol (2015) 15:68–73. doi: 10.1016/j.coph.2015.02.003
2. Syam N, Chatel S, Onathalil LC, Sottas V, Rougier JS, Baruteau A, et al. Variants of transient receptor potential melastatin member 4 in childhood atraoventricular block. J Am Heart Assoc (2016) 5:e001625. doi: 10.1161/JAHA.116.001625
3. Launay P, Fleig A, Perraud AM, Penner R, Kinet JP. TRPM4 is a Ca2+-activated nonselective cation channel mediating cell membrane depolarization. Cell (2002) 109:397–407. doi: 10.1016/s0092-8674(02)00719-5
4. Winklek PA, Huang Y, Sun W, Du J, Lu W. Electron cryo-microscopy structure of a human TRPM4 channel. Nature (2017) 552:200–4. doi: 10.1038/nature24674
5. Guo J, She J, Zeng W, Chen Q, Bai X, Jiang Y. Structure of the calcium-activated, non-selective cation channel TRPM4. Nature (2017) 552:205–9. doi: 10.1038/nature24997
6. Autzen HE, Myasnikov AG, Campbell MG, Asarnow D, Julius D, Cheng Y. Structure of the human TRPM4 ion channel in a lipid nanodisc. Science (2018) 359:228–32. doi: 10.1126/science.aar4410
7. Duan J, Li Z, Li J, Santa-Cruz A, Sanchez-Martinez S, Zhang J, et al. Structure of full-length human TRPM4. Proc Natl Acad Sci U S A. (2018) 115:2377–82. doi: 10.1073/pnas.1723094115
8. Gonzalez AL, Garcia ZL, Amberg GC, Earley S. Pharmacological inhibition of TRPM4 hyperpolarizes vascular smooth muscle. Am J Physiol Cell Physiol (2010) 299:C1195–202. doi: 10.1152/ajpcell.00269.2010
9. Wang C, Naruse K, Takahashi K. Role of the TRPM4 channel in cardiovascular physiology and pathophysiology. Cells (2018) 7. doi: 10.3390/cells7060062
10. Cheng H, Beck A, Launay P, Gross SA, Stokes AJ, Kinet JP, et al. TRPM4 controls insulin secretion in pancreatic beta-cells. Cell Calcium. (2007) 41:51–61. doi: 10.1016/j.cca.2006.04.032
11. Earley S. TRPM4 channels in smooth muscle function. Pflugers Arch (2013) 465:1223–31. doi: 10.1007/d01042-013-1250-z
12. Weber KS, Hildner K, Murphy KM, Allen PM. TRPM4 differentially regulates Th1 and Th2 function by altering calcium signaling and NFAT localization. J Immunol (2010) 185:2836–46. doi: 10.4049/jimmunol.1008880
13. Barbet G, Demion M, Mouta IC, Serafini N, Leger T, Vrtovsnik F, et al. The calcium-activated nonselective cation channel TRPM4 is essential for the migration but not the maturation of dendritic cells. Nat Immunol (2008) 9:1148–56. doi: 10.1038/nature07648
14. Vennekens R, Olausson J, Meisner M, Bloch W, Mathur I, Philipp SE, et al. Increased IgE-dependent mast cell activation and anaphylactic responses in mice lacking the calcium-activated nonselective cation channel TRPM4. Nat Immunol (2007) 8:312–20. doi: 10.1038/ni1441
15. Kruse M, Schulze-Bahr E, Corfield V, Beckmann A, Stallmeyer B, Kurtbay G, et al. Impaired endocytosis of the ion channel TRPM4 is associated with human progressive familial heart block type I. J Clin Invest. (2009) 119:2737–44. doi: 10.1172/JCI38292
16. Liu H, El Zein L, Kruse M, Guinamard R, Beckmann A, Bozio A, et al. Gain-of-function mutations in TRPM4 cause autosomal dominant isolated cardiac conduction disease. Circ Cardiovasc Genet (2010) 3:374–85. doi: 10.1161/CIRCGENETICS.109.930667
17. Wang H, Xu Z, Lee BH, Vu S, Hu L, Lee M, et al. Gain-of-Function mutations in TRPM4 activation gate cause progressive symmetric erythrodermatodermia. J Invest Dermatol (2019) 139:1089–97. doi: 10.1016/j.jid.2018.10.044
18. Launay P, Cheng H, Srivatsan S, Penner R, Fleig A, Kinet JP. TRPM4 regulates calcium oscillations after T cell activation. Science (2004) 306:1374–7. doi: 10.1126/science.1098845

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1025499/full#supplementary-material
19. Serafini N, Dahdah A, Barbet G, Demion M, Attout T, Gautier G, et al. The TRPM4 channel controls monocyte and macrophage, but not neutrophil, function for survival in sepsis. J Immunol (2012) 189:3689–99. doi: 10.4049/jimmunol.1102969

20. Shimizu T, Owsianik G, Freichel M, Flockerzi V, Nilius B, Vennekens R. TRPM4 regulates migration of mast cells in mice. Cell Calcium. (2009) 45:226–32. doi: 10.1016/j.ceca.2008.10.005

21. Schattling B, Steinbach K, Thies E, Kruse M, Menigoz A, Ufer F, et al. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med (2012) 18:1805–11. doi: 10.1038/nm.3015

22. Li F, Adase CA, Zhang LJ. Isolation and culture of primary mouse keratinocytes from neonatal and adult mouse skin. J Vis Exp (2017) 125:56027. doi: 10.3791/56027

23. Kim KH, Sederstrom JM. Assaying cell cycle status using flow cytometry. Curr Protoc Mol Biol (2015) 111:28601–11. doi: 10.1002/0471142727.mb2806s111

24. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol (2009) 182:5836–45. doi: 10.4049/jimmunol.0802999

25. Shi Z, Garcia-Melchor E, Wu X, Getschman AE, Nguyen M, Rowland DJ, et al. Targeting the CCR6/CCL20 axis in entheseal and cutaneous inflammation. Arthritis Rheumatol (2021) 73:2271–81. doi: 10.1002/art.41882

26. Shi Z, Wu X, Santos Rocha C, Rolston M, Garcia-Melchor E, Huynh M, et al. Short-term Western diet intake promotes IL-23-mediated skin and joint inflammation accompanied by changes to the gut microbiota in mice. J Invest Dermatol (2021) 141:1780–91. doi: 10.1016/j.jid.2020.11.032

27. Gerzanich V, Woo SK, Vennekens R, Tsymbalyuk O, Ivanova S, Ivanov A, et al. De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injury. Nat Med (2009) 15:185–91. doi: 10.1038/nm.1899

28. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing gammacell T cells in skin inflammation. Immunity (2011) 35:596–610. doi: 10.1016/j.immuni.2011.08.001

29. Mabuchi T, Takekoshi T, Hwang ST. Epidermal CCR6+ gammadelta T cells are major producers of IL-22 and IL-17 in a murine model of psoriasisform dermatitis. J Immunol (2011) 187:5026–31. doi: 10.4049/jimmunol.1101817

30. Yu S, Wu X, Zhou Y, Han D, Anderson LS, Simon SI, et al. Is CCR6 required for the development of psoriasisform dermatitis in mice? J Invest Dermatol (2019) 139:485–8. doi: 10.1016/j.jid.2018.07.036

31. Furue M, Furue K, Tsuji G, Nakahara T. Interleukin-17A and keratinocytes in psoriasis. Int J Mol Sci (2020) 21:1275. doi: 10.3390/ijms21041275

32. Nir M, Tanzer F. Progressive symmetric erythrokeratodermia. Dermatologica (1978) 156:268–73. doi: 10.1159/000250927

33. He Y, Chang Y, Peng Y, Zhu J, Liu K, Chen J, et al. Glibenclamide directly prevents neuroinflammation by targeting SUR1-TRPM4-Mediated NLRP3 inflammasome activation in microglia. Mol Neurobiol (2022) 59:6590–607. doi: 10.1007/s12035-022-02999-x

34. Woo SK, Kwon MS, Ivanov A, Gerzanich V, Simard JM. The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (Trpm4) channel. J Biol Chem (2013) 288:3655–67. doi: 10.1074/jbc.M112.428219

35. Malysz J, Maxwell SE, Yarotskyy V, Petkov GV. TRPM4 channel inhibitors 9-phenanthrol and glibenclamide differentially decrease guinea pig detrusor smooth muscle whole-cell cation currents and phasic contractions. Am J Physiol Cell Physiol (2020) 308:C406–C21. doi: 10.1152/ajpcell.00055.2019

36. Demion M, Bois P, Launay P, Guinamard R. TRPM4, a Ca2+-activated nonselective cation channel in mouse sino-atrial node cells. Cardiovasc Res (2007) 73:531–8. doi: 10.1016/j.cardiores.2006.11.023

37. Othathil LC, Delalande C, Bianchi B, Nemeth G, Kappel S, Thomet U, et al. Identification of potent and selective small molecule inhibitors of the cation channel TRPM4. Br J Pharmacol (2018) 175:2504–19. doi: 10.1111/bph.14220